Journal
JOURNAL OF VIROLOGY
Volume 85, Issue 1, Pages 410-421Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01826-10
Keywords
-
Categories
Funding
- Medical Research Council, United Kingdom
- Wellcome Trust, United Kingdom
- National Institute for Health Research Biomedical Research Centre
- Thailand Tropical Disease Research Program T2
- Thailand National Centre for Genetic Engineering and Biotechnology
- Medical Research Council [G0400720, G0801508, G0600000] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0507-10303] Funding Source: researchfish
- MRC [G0400720, G0600000, G0801508] Funding Source: UKRI
Ask authors/readers for more resources
The evolution of dengue viruses has resulted in four antigenically similar yet distinct serotypes. Infection with one serotype likely elicits lifelong immunity to that serotype, but generally not against the other three. Secondary or sequential infections are common, as multiple viral serotypes frequently cocirculate. Dengue infection, although frequently mild, can lead to dengue hemorrhagic fever (DHF) which can be life threatening. DHF is more common in secondary dengue infections, implying a role for the adaptive immune response in the disease. There is currently much effort toward the design and implementation of a dengue vaccine but these efforts are made more difficult by the challenge of inducing durable neutralizing immunity to all four viruses. Domain 3 of the dengue virus envelope protein (ED3) has been suggested as one such candidate because it contains neutralizing epitopes and it was originally thought that relatively few cross-reactive antibodies are directed to this domain. In this study, we performed a detailed analysis of the anti-ED3 response in a cohort of patients suffering either primary or secondary dengue infections. The results show dramatic evidence of original antigenic sin in secondary infections both in terms of binding and enhancement activity. This has important implications for dengue vaccine design because heterologous boosting is likely to maintain the immunological footprint of the first vaccination. On the basis of these findings, we propose a simple in vitro enzyme-linked immunosorbent assay (ELISA) to diagnose the original dengue infection in secondary dengue cases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available